Get instant alerts when news breaks in your stocks. Claim your 2-week free trial offer to StreetInsider Premium here.
“The Radixact System provides the radiotherapy team broadened abilities over the largest selection of patient cases, in the routine towards the most complex, with precision, speed and efficient workflows,” stated Joshua H. Levine, president and ceo of Accuray.
Accuray Incorporated (Nasdaq: ARAY) introduced it’s received 510(k) clearance in the U.S. Fda (Food and drug administration) because of its Radixact Treatment Delivery Platform. Accuray also received 510(k) clearance because of its new treatment planning and knowledge management systems, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. These next-gen software and hardware solutions which, together, from the new Radixact system, enable faster, more effective delivery of very precise treatment to some wider selection of cancer patients, including individuals going through retreatment. The brand new Radixact system signifies a significant advance within the evolution from the TomoTherapy® System in treatment speed and simplicity of use.
Accuray will initiate commercial discharge of the Radixact System late within the first quarter of fiscal year 2017 (This summer – September 2016).
Based on Jennifer Smilowitz, PhD, clinical affiliate professor College of Wisconsin Med school and Public Health, who had been active in the growth and development of the brand new radiotherapy technology, “The Radixact System develops upon the initial talents from the TomoTherapy platform. Broadened delivery abilities enable treatment with image-led, intensity-modulated radiotherapy (IG-IMRT, an very accurate type of radiotherapy) for an broadened selection of patients. New database features result in the ring gantry-based system even simpler to function and integrate inside a radiation oncology department.”
The machine includes a more effective straight line accelerator, MVCT imaging and helical treatment delivery, so physicians can use highly conformal and homogenous dose distributions to the target volume, while precisely sparing normal healthy tissue during each treatment fraction. The brand new Accuray Precision Treatment Planning System with wise, automated workflows and midcourse decision-making tools, allows physicians to evolve delivery to alterations in tumor size, shape and placement inside the patient.